NSW Regional Cancer Research Network, in collaboration with the Maridulu Budyari Gumal (SPHERE) Cancer CAG and Sydney Cancer Partners is hosting the 2024 NSW Cancer Research Education State-wide Seminar Series. These online seminars will be held on the 3rd Tuesday of each month.
This session will focus on hypomethylating agents (HMAs), which are used to treat people living with acute myeloid leukaemia (AML) and myelodysplasia. While these epigenetic therapies extend survival in many patients, low response rates and therapy-resistant relapse remain significant challenges. Relapse is thought to arise from cells that survive and adapt to treatment, so single-cell multi-omic analysis and colony assays been used to characterise the heterogeneous response of AML cells to HMAs. This has revealed treatment-induced heterogeneity as well as processes that facilitate cell growth after treatment. Join us to see how single-cell analysis with linked functional assays can identify new treatment strategies for cancer.
Dr Heather Lee. NHMRC Research Fellow, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, The University of Newcastle, Australia.
Please select ‘NSW Regional Cancer Research Network’ as the Centre to which you belong.
The NSW Cancer Research Statewide Seminar series is supported by Translational Research Capacity Building Grants funded by the Cancer Institute NSW.